Canaccord Genuity analyst Edward Nash maintained a Buy rating on Madrigal Pharmaceuticals yesterday and set a price target of $428.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Edward Nash has given his Buy rating due to a combination of factors that highlight Madrigal Pharmaceuticals’ promising position in the market. The company’s flagship product, Rezdiffra, is the first and only FDA-approved therapy for MASH, and it has shown impressive sales growth, with a 55% increase in the second quarter of 2025, surpassing both the firm’s and market expectations. This strong performance underscores the product’s potential and the company’s strategic positioning.
Moreover, Madrigal’s recent acquisition of global rights for SYH2086, an oral GLP-1RA, to develop a combination therapy with Rezdiffra, signifies a forward-thinking approach that could enhance their market offering. The company’s confidence is further bolstered by positive feedback from hepatologists and the promising data from their clinical studies, which suggest continued clinical benefits for patients. These factors collectively contribute to Nash’s optimistic outlook and the reiteration of a Buy rating with a price target of $428.
In another report released yesterday, UBS also maintained a Buy rating on the stock with a $523.00 price target.